Srinath Sanda

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Antoinette Moran, Brian N. Bundy, Dorothy Becker et al. · The Lancet · 2013 · 351 citations · Full text

Inflammation, Metabolic Syndrome, Type 1 +11

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

S. Alice Long, Mary Rieck, Srinath Sanda et al. · Diabetes · 2012 · 306 citations · Full text

Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1

Jenny E. Kanter, Farah Kramer, Shelley Barnhart et al. · Proceedings of the National Academy of Sciences · 2012 · 300 citations · Full text

Acyl-coa Synthetase 1, Immunology, Inflammatory Macrophage Phenotype +18

The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells

Anya Schneider, Mary Rieck, Srinath Sanda et al. · The Journal of Immunology · 2008 · 294 citations · Full text

Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects

S. Alice Long, Karen Cerosaletti, Paul L. Bollyky et al. · Diabetes · 2009 · 274 citations · Full text